Warren Woessner is a registered patent attorney and a founding shareholder of Schwegman, Lundberg & Woessner. His practice focuses on chemical patent law, including biotechnology, pharmaceuticals, vaccines, medical treatments, diagnostics, and biofuels and agricultural chemistry, including related opinion and licensing matters.
Warren received his B.A. in chemistry (1966) from Cornell University, his Ph.D. (organic chemistry, 1971) and his law degree (J.D., cum laude, 1981) from the University of Wisconsin – Madison. From 1972-1978 he worked for Miles Laboratories in new drug research. Warren was an associate attorney at Kenyon & Kenyon from 1981-1984, and then joined Merchant & Gould in Minneapolis. He founded their chemical practice group and became a partner in 1989. Warren also co-founded the Biotechnology Committee of the Minnesota Intellectual Property Law Association. He has published and spoken widely on legal topics, was the 1993-1995 chair of the Chemical Practice Committee of the American Intellectual Property Law Association, chaired the Biotechnology Committee (2003-2005) and has served as a member of the Amicus Committee. He co-authored the AIPLA amicus briefs to the Federal Circuit and the Supreme Court in J.E.M. Ag Supply v. Pioneer Hi-Bred. Warren is a Certified Licensing Professional
More Legal and Business Bylines From Warren Woessner
- Federal Circuit Denies En Banc Review of Athena v. Mayo - (Posted On Sunday, July 07, 2019)
- Cutting Through the Patent Thicket – The Little Bill that Couldn’t - (Posted On Tuesday, June 18, 2019)
- Senate Subcommittee Hearing of Patent Eligibility Wrap Up – Now What? - (Posted On Thursday, June 13, 2019)
- Senate Subcommittee on IP Feels our PAIN - (Posted On Thursday, June 06, 2019)
- Bipartisan “Draft Bill” to Amend ss. 100, 101 and 112 Released for Comment - (Posted On Friday, May 24, 2019)
- Novartis v. West-Ward – Lead Compound Analysis v. Motivation to Combine - (Posted On Monday, May 20, 2019)
- Is the “Blocking Patent” Doctrine Part of the Obviousness Analysis? - (Posted On Friday, May 17, 2019)
- Athena III – Should the Discovery of a Naturally-Occurring Correlation Encompass Recognition of its Practical Utility? - (Posted On Tuesday, May 07, 2019)
- Senate Committee Releases Outline for Section 101 Reform - (Posted On Thursday, April 18, 2019)
- Athena’s Petition for Rehearing En Banc – Not All Diagnostic Claims are Equal Under s. 101 - (Posted On Monday, April 15, 2019)
The National Law Review has awarded Warren Woesssner, shareholder at Schwegman, Lundberg & Woessner, P.A., a Go-To Thought Leadership Award for Mr. Woessner’s ongoing coverage and analysis of patent disputes, updates to USPTO processes and interviews and profiles of prominent federal agency appointees. He provides NLR's readers with a well-rounded view of issues impacting patent law in the U.S. The cases of Yu v. Apple and CareDx v. Natera are especially notable, detailing the complicated intersections between intellectual property, technology, and health law.
Warren Woessner and his thought leadership on Life Sciences Intellectual Property has been selected for a National Law Review Go-To Thought Leadership Award. Mr. Woessner’s coverage of patent litigation, the Patent Trial and Appeals Board and the Court of Appeals for the Federal Circuit and how those decisions fit into the larger landscape of patent litigation is an invaluable resource for NLR readers. You can subscribe to his Patents 4 Life blog here.